THE STANDARD OF CARE IN RELAPSED REFRACTORY CD30+ LYMPHOMA
CD30-positive (CD30+) lymphomas are a heterogeneous group of hematological malignancies that share the same antigen. Over recent decades, advances in therapeutic management of these diseases have considerably improved clinical outcomes. Overall, the two main CD30+ lymphomas – Hodgkin’s lymphoma and...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Medical Journal
2014-07-01
|
| Series: | European Medical Journal Hematology |
| Subjects: | |
| Online Access: | https://emj.emg-health.com/wp-content/uploads/sites/2/2018/02/The-Standard-of-Care-in-Relapsed-Refractory-CD30-Lymphoma.pdf |
| _version_ | 1818550639241723904 |
|---|---|
| author | Martin Hutchings |
| author_facet | Martin Hutchings |
| author_sort | Martin Hutchings |
| collection | DOAJ |
| description | CD30-positive (CD30+) lymphomas are a heterogeneous group of hematological malignancies that share the same antigen. Over recent decades, advances in therapeutic management of these diseases have considerably improved clinical outcomes. Overall, the two main CD30+ lymphomas – Hodgkin’s lymphoma and systemic anaplastic large cell lymphoma – are associated with a favourable prognosis after first-line therapy. Nevertheless, optimal therapeutic strategies are needed to manage relapsed or refractory CD30+ lymphomas. The introduction of novel targeted approaches, such as brentuximab vedotin (BV), expands the therapeutic armamentarium and provides new perspectives in terms of clinical efficacy despite heavily pretreated disease, with reasonable toxicity to patients whose quality of life is often impaired by the disease and repeated treatments. The standard of care (SoC) for these malignancies is being refined and will be clarified with results from ongoing and upcoming Phase II/III clinical trials. Clinical studies are currently assessing the use of BV in a broad range of CD30+ lymphomas. Over time, frontline strategies and SoC will be refined in order to improve outcomes for patients with relapsed disease, while allowing clinicians to expand patient selection and provide long-term remission in a wide variety of clinical settings. |
| first_indexed | 2024-12-12T08:49:10Z |
| format | Article |
| id | doaj.art-d6e7c8b9f34b46e1ade92ddd3c9c3236 |
| institution | Directory Open Access Journal |
| issn | 2053-6631 |
| language | English |
| last_indexed | 2024-12-12T08:49:10Z |
| publishDate | 2014-07-01 |
| publisher | European Medical Journal |
| record_format | Article |
| series | European Medical Journal Hematology |
| spelling | doaj.art-d6e7c8b9f34b46e1ade92ddd3c9c32362022-12-22T00:30:20ZengEuropean Medical JournalEuropean Medical Journal Hematology2053-66312014-07-01216269THE STANDARD OF CARE IN RELAPSED REFRACTORY CD30+ LYMPHOMAMartin Hutchings0Department of Hematology, Rigshospitalet, Copenhagen, DenmarkCD30-positive (CD30+) lymphomas are a heterogeneous group of hematological malignancies that share the same antigen. Over recent decades, advances in therapeutic management of these diseases have considerably improved clinical outcomes. Overall, the two main CD30+ lymphomas – Hodgkin’s lymphoma and systemic anaplastic large cell lymphoma – are associated with a favourable prognosis after first-line therapy. Nevertheless, optimal therapeutic strategies are needed to manage relapsed or refractory CD30+ lymphomas. The introduction of novel targeted approaches, such as brentuximab vedotin (BV), expands the therapeutic armamentarium and provides new perspectives in terms of clinical efficacy despite heavily pretreated disease, with reasonable toxicity to patients whose quality of life is often impaired by the disease and repeated treatments. The standard of care (SoC) for these malignancies is being refined and will be clarified with results from ongoing and upcoming Phase II/III clinical trials. Clinical studies are currently assessing the use of BV in a broad range of CD30+ lymphomas. Over time, frontline strategies and SoC will be refined in order to improve outcomes for patients with relapsed disease, while allowing clinicians to expand patient selection and provide long-term remission in a wide variety of clinical settings.https://emj.emg-health.com/wp-content/uploads/sites/2/2018/02/The-Standard-of-Care-in-Relapsed-Refractory-CD30-Lymphoma.pdflymphomacd30brentuximabhodgkin’s lymphomasystemic anaplastic large cell lymphoma |
| spellingShingle | Martin Hutchings THE STANDARD OF CARE IN RELAPSED REFRACTORY CD30+ LYMPHOMA European Medical Journal Hematology lymphoma cd30 brentuximab hodgkin’s lymphoma systemic anaplastic large cell lymphoma |
| title | THE STANDARD OF CARE IN RELAPSED REFRACTORY CD30+ LYMPHOMA |
| title_full | THE STANDARD OF CARE IN RELAPSED REFRACTORY CD30+ LYMPHOMA |
| title_fullStr | THE STANDARD OF CARE IN RELAPSED REFRACTORY CD30+ LYMPHOMA |
| title_full_unstemmed | THE STANDARD OF CARE IN RELAPSED REFRACTORY CD30+ LYMPHOMA |
| title_short | THE STANDARD OF CARE IN RELAPSED REFRACTORY CD30+ LYMPHOMA |
| title_sort | standard of care in relapsed refractory cd30 lymphoma |
| topic | lymphoma cd30 brentuximab hodgkin’s lymphoma systemic anaplastic large cell lymphoma |
| url | https://emj.emg-health.com/wp-content/uploads/sites/2/2018/02/The-Standard-of-Care-in-Relapsed-Refractory-CD30-Lymphoma.pdf |
| work_keys_str_mv | AT martinhutchings thestandardofcareinrelapsedrefractorycd30lymphoma AT martinhutchings standardofcareinrelapsedrefractorycd30lymphoma |